CCTG has opened the anticipated international brain cancer study CCTG CE9 (LUMOS2) - joining forces with the Australian Cooperative Trials Group for Neuro-Oncology (COGNO) to make enrollment accessible to Canadian patients.
Novel Therapeutics in Younger Patients with High-Risk AML (MM1YA-S01)
MODERN: An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of Adjuvant Therapy in Urothelial Cancer
Radiotherapy to Block (CURB2) Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
Comparing Palliative Stereotactic Body Radiotherapy vs. Palliative Standard Radiotherapy in Patients with Advanced Head and Neck Cancer
The CCTG ES3 NEEDS international esophageal cancer clinical trial is now opened in Canada. The study is investigating whether delaying surgery for patients with squamous cell carcinoma of the esophagus is as good as the current treatment.
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
Botensilimab + Balstilimab or Botensilimab Alone vs Best Supportive Care as Therapy in Chemo-refractory, Advanced, Colorectal Adenocarcinoma: The BATTMAN Trial
STRIDE (durvalumab + tremelimumab) with Lenvatinib vs STRIDE Alone in Patients with Unresectable Hepatocellular Carcinoma (SLIDE-HCC)
CALMS: Combination Therapy with Luspatercept in Lower Risk MDS CTEP approval: 2024AUG27 (date of US Steering Committee Evaluation)
Lanreotide for the Prevention of Postoperative Pancreatic Fistula
Dr. McKenzie is a radiation oncologist with extensive experience in genitourinary oncology, neurooncology and palliative oncology. He currently works as a radiation oncologist at BC Cancer Vancouver. He also is the co-chair of the CCTG Supportive Care Committee. In this video, McKenzie addresses the wide variety of trials the Supportive Care Committee is involved with, as well as potential avenues for new trials that may extend beyond the jurisdiction of cancer research.
The CCTG IND.225 trial: A Phase II Study of the Assessment of Response to Pembrolizumab in Metastatic Melanoma: CT Texture Analysis as a Predictive Biomarker has been permanently closed/terminated.
CCTG SC.24, A Randomized Phase II/III Study Comparing Stereotactic Body Radiotherapy (SBRT) versus Conventional Palliative Radiotherapy (CRT) for Patients with Spinal Metastases, has been closed to accrual after the completion of target accrual. Although the trial is closed accrual, treatment and follow up of patients will continue according to the protocol.
The purpose of this study is to find out if SBRT is better than CRT at controlling pain in the spine 3 months after receiving treatment.
Registration for the 2019 Canadian Cancer Research Conference (CCRC) is now open.The conference will be of interest to cancer researchers, clinicians, and decision-makers across disciplines and at all stages of their career.
The Guidance Document: Part C, Division 5 of the Food and Drug Regulations “Drugs for Clinical Trials Involving Human Subjects” (GUI-0100) was published online today, August 20, 2019 and can be found on the Health Canada website at:
The CCTG Central Operations and Statistics Office located at Queen's University in Kingston, Ontario has a job opening for a two Study Coordinators and a Research Associate.
Sites may record protocol training in the centre admin menu of the CCTG Site Training Utility (STU). CCTG has offered protocol-specific training for sites since 2012. To continue to be GCP compliant, protocol training has been required for all participants with delegated duties on the trial participants list for all new trials centrally activated after July 1, 2018. This requirement is stated in the Central Activation Letter and Notice of Health Canada Submission
CCTG Director, Dr Janet Dancey will be a Keynote Speaker at the The 5th International Clinical Trials Methodology Conference is being held 6-9th October 2019 in Brighton UK. Dr Dancey will be speaking on the The Evolution of Academic Sponsored Clinical Trials in the 21st Century: Lessons Learned at the Canadian Cancer Trials Group.
